Inorbit Therapeutics ab

Unique Drug Design to Avoid Drug Induced Liver Injury

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Gothenburg, Sweden
  • Currency SEK
  • Founded March 2015
  • Employees 2
  • Incorporation Type Other
  • Website inorbittx.com

Company Summary

Inorbit is a drug discovery company aiming to resurrect drugs with proven human efficacy, but which failed due to Drug-Induced liver Injury, by applying its novel unique chemistry platform. Inorbit is currently focused on target markets like the fatty liver diseases NAFLD and NASH. The company has a virtual nature, relying on an excellent network of collaborators. In this way, Inorbit performs efficient and cost-effective drug discovery.

Team

  • CEO / Chairman

    Former Vice President, Metabolic Diseases and Translational Medicine with Piramal Healthcare, Mumbai, India. Previously with AstraZeneca, 7TM Pharma, Novo Nordisk, and Novartis. Bert has a strong record in metabolic diseases, with focus on NAFLD/NASH and obesity. He took several discovery programs to the clinic

  • Former team leader for Medicinal Chemistry groups in AstraZeneca. Robert brings extensive experience from Millennium Pharmaceutical, Cambridge Discovery Chemistry, and Roche. He has broad experience in the delivery of medicinal chemistry projects from lead generation and lead optimization to pre-clinic and in patent strategy. Robert has deep drug discovery experience in the therapeutic areas of cardiovascular & metabolic diseases and oncology.

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free